Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion, Quest Ink Deal to Sell OVA1 in India

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Vermillion today announced an agreement with Quest Diagnostics for the launch of the OVA1 ovarian cancer test in India.

The two firms are targeting the launch for the second quarter. In a statement, Gail Page, president and CEO of Austin, Texas-based Vermillion said that with 350 million women, India is an "outstanding market opportunity. … Vermillion is now poised for growth both domestically and internationally as we continue to develop our international strategy in concert with the efforts already underway in the US."

Quest already was marketing OVA1, which received clearance from the US Food and Drug Administration in September 2009, in the US. The test was the first protein-based in vitro diagnostic multivariate index assay to receive such approval.

Financial and other terms of today's deal were not disclosed.

Quest operates a 65,000 square-foot facility in Gurgaon, in the National Capital Region of India, that offers more than 700 tests using advanced technology and quality standards that comply with global best practices, Vermillion said.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.